Using an exon microarray to identify a global profile of gene expression and alternative splicing in K562 cells exposed to sodium valproate

Zhang,Xiang-Zhong; Yin,Ai-Hua; Zhu,Xiao-Yu; Ding,Qian; Wang,Chun-Huai; Chen,Yun-Xian

doi:10.3892/or.2011.1601

Using an exon microarray to identify a global profile of gene expression and alternative splicing in K562 cells exposed to sodium valproate

Authors:
- Xiang-Zhong Zhang
- Ai-Hua Yin
- Xiao-Yu Zhu
- Qian Ding
- Chun-Huai Wang
- Yun-Xian Chen
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China
Published online on: December 21, 2011 https://doi.org/10.3892/or.2011.1601
Pages: 1258-1265

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the effect of valproate treatment on the K562 cell line, a model for chronic myelogenous leukaemia, the growth and survival of the K562 cell line were investigated using the Annexin-V/PI dual staining method, and global profiles of gene expression and alternative splicing in K562 cells were assessed using exon microarrays. A significant increase in cell apoptosis was observed in valproate-exposed K562 cells using flow cytometry. A total of 628 transcripts were identified as being significantly differentially expressed. The number of genes demonstrating increased expression levels was greater than the number of genes demonstrating decreased expression levels (445 genes vs. 183 genes, respectively). The significant enrichment analysis of GO terms for the differentially expressed genes revealed that these genes are involved in many important biological processes such as apoptosis. Six of the genes observed to be differentially expressed that might be involved in apoptosis were selected to undergo qRT-PCR validation. In total, 198 candidates of alternative splicing variants were identified. Among them, three alternative splicing events were selected for validation, and CBLC and TBX1 were confirmed to be alternatively spliced by semi-nested PCR. In conclusion, valproate exposure facilitated cell apoptosis, altered mRNA expression and alternative splicing events in the K562 cell line.

View Figures

View References

1	Carlson A, Berkowitz JM, Browning D, Slamon DJ, Gasson JC and Yates KE: Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias. DNA Cell Biol. 24:311–316. 2005. View Article : Google Scholar : PubMed/NCBI
2	Gaillard JB, Arnould C, Bravo S, et al: Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. Mol Cancer Ther. 9:3083–3089. 2010. View Article : Google Scholar : PubMed/NCBI
3	Matulic M, Paradzik M, Puskaric BJ, Stipic J and Antica M: Analysis of Ikaros family splicing variants in human hematopoietic lineages. Coll Antropol. 34:59–62. 2010.PubMed/NCBI
4	Vassen L, Khandanpour C, Ebeling P, et al: Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. Int J Hematol. 89:422–430. 2009. View Article : Google Scholar : PubMed/NCBI
5	Wihlidal P, Varga F, Pfeilstocker M and Karlic H: Expression and functional significance of osteocalcin splicing in disease progression of hematological malignancies. Leuk Res. 30:1241–1248. 2006. View Article : Google Scholar : PubMed/NCBI
6	Rogers SL, Zhao Y, Jiang X, Eaves CJ, Mager DL and Rouhix A: Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia. Mol Cancer. 9:412010. View Article : Google Scholar : PubMed/NCBI
7	Luco RF, Allo M, Schor IE, Kornblihtt AR and Misteli T: Epigenetics in alternative pre-mRNA splicing. Cell. 144:16–26. 2011. View Article : Google Scholar : PubMed/NCBI
8	Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM and Misteli T: Regulation of alternative splicing by histone modifications. Science. 327:996–1000. 2010. View Article : Google Scholar : PubMed/NCBI
9	Milutinovic S, D’Alessio AC, Detich N and Szyf M: Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis. 28:560–571. 2007. View Article : Google Scholar : PubMed/NCBI
10	Brichta L, Hofmann Y, Hahnen E, et al: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 12:2481–2489. 2003. View Article : Google Scholar : PubMed/NCBI
11	Langer W, Sohler F, Leder G, et al: Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer. BMC Genomics. 11:6762010. View Article : Google Scholar : PubMed/NCBI
12	Moller-Levet CS, Betts GN, Harris AL, Homer JJ, West CM and Miller CJ: Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis. PLoS Comput Biol. 5:e10005712009. View Article : Google Scholar : PubMed/NCBI
13	Chen H, Guo Y, Hu M, Duan W, Chang G and Li C: Differential expression and alternative splicing of genes in lumbar spinal cord of an amyotrophic lateral sclerosis mouse model. Brain Res. 1340:52–69. 2010. View Article : Google Scholar : PubMed/NCBI
14	Johnson MB, Kawasawa YI, Mason CE, et al: Functional and evolutionary insights into human brain development through global transcriptome analysis. Neuron. 62:494–509. 2009. View Article : Google Scholar : PubMed/NCBI
15	Shi YH, Zhu SW, Mao XZ, et al: Transcriptome profiling, molecular biological, and physiological studies reveal a major role for ethylene in cotton fiber cell elongation. Plant Cell. 18:651–664. 2006. View Article : Google Scholar : PubMed/NCBI
16	Gardina PJ, Clark TA, Shimada B, et al: Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics. 7:3252006. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
18	Leparc GG and Mitra RD: A sensitive procedure to detect alternatively spliced mRNA in pooled-tissue samples. Nucleic Acids Res. 35:e1462007. View Article : Google Scholar : PubMed/NCBI
19	Romanski A, Bacic B, Bug G, et al: Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica. 89:419–426. 2004.PubMed/NCBI
20	Morotti A, Cilloni D, Messa F, et al: Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer. 106:1188–1196. 2006. View Article : Google Scholar : PubMed/NCBI
21	Raffoux E, Cras A, Recher C, et al: Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 1:34–42. 2010.PubMed/NCBI
22	Fredly H, Stapnes Bjornsen C, Gjertsen BT and Bruserud O: Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia: a report of five cases. Hematology. 15:338–343. 2010. View Article : Google Scholar : PubMed/NCBI
23	Buchi F, Pastorelli R, Ferrari G, et al: Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. Leuk Res. 35:921–923. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kircher B, Schumacher P, Petzer A, et al: Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph⁺ ALL and CML cells in vitro. Eur J Haematol. 83:48–56. 2009. View Article : Google Scholar : PubMed/NCBI
25	Cheng YC, Lin H, Huang MJ, Chow JM, Lin S and Liu HE: Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res. 31:1403–1411. 2007. View Article : Google Scholar : PubMed/NCBI
26	Bokelmann I and Mahlknecht U: Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med. 14:20–27. 2008. View Article : Google Scholar : PubMed/NCBI
27	Stamatopoulos B, Meuleman N, De Bruyn C, et al: Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia. 23:2281–2289. 2009. View Article : Google Scholar : PubMed/NCBI
28	Khanim FL, Bradbury CA, Arrazi J, et al: Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol. 144:332–341. 2009. View Article : Google Scholar : PubMed/NCBI
29	Skotheim RI and Nees M: Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol. 39:1432–1449. 2007. View Article : Google Scholar : PubMed/NCBI
30	He C, Zhou F, Zuo Z, Cheng H and Zhou R: A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis. PLoS One. 4:e47322009. View Article : Google Scholar : PubMed/NCBI
31	Fackenthal JD and Godley LA: Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech. 1:37–42. 2008. View Article : Google Scholar : PubMed/NCBI
32	Schwerk C and Schulze-Osthoff K: Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell. 19:1–13. 2005. View Article : Google Scholar : PubMed/NCBI
33	Wang Q and Silver PA: Genome-wide RNAi screen discovers functional coupling of alternative splicing and cell cycle control to apoptosis regulation. Cell Cycle. 9:4419–4421. 2010. View Article : Google Scholar : PubMed/NCBI
34	Kim E, Goren A and Ast G: Insights into the connection between cancer and alternative splicing. Trends Genet. 24:7–10. 2008. View Article : Google Scholar
35	Makishima H, Cazzolli H, Szpurka H, et al: Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 27:6109–6116. 2009. View Article : Google Scholar : PubMed/NCBI
36	Keane MM, Ettenberg SA, Nau MM, et al: cbl-3: a new mammalian cbl family protein. Oncogene. 18:3365–3375. 1999. View Article : Google Scholar : PubMed/NCBI